OMNOVA Solutions Inc. (NYSE:OMN) tinted loss of -0.47% (-0.05 points) to US$10.55. The volume of 0.07 Million shares climbed down over an trading activity of 144.55 Million shares. EPS ratio determined by looking at last 12 month figures is -2.01. Over the same time span, the stock marked US$11.9 as its best level and the lowest price reached was US$8.1. The corporation has a market cap of US$481.71 Million.
OMNOVA Solutions Inc. (NYSE:OMN)’s earnings per share has been growing at a -40.9 percent rate over the past 5 year when average revenue increase was noted as -7 percent. The return on equity ratio or ROE stands at -102.9 percent while most common profitability ratio return on investment (ROI) was -22.6 percent. The company’s institutional ownership is monitored at 93.3 percent. The company’s net profit margin has achieved the current level of -10.7 percent and possesses 25.9 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2.25. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Unity Biotechnology, Inc. (NASDAQ:UBX) is worth US$618.5 Million and has recently fallen -0.47% to US$14.76. The latest exchange of 0.12 Million shares is below its average trading activity of 152.5 Million shares. The day began at US$14.87 but the price moved to US$14.51 at one point during the trading and finally capitulating to a session high of US$15.31. The stock tapped a 52-week high of US$20.48 while the mean 12-month price target for the shares is US$24.67.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 447.54. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 0.09%, it carries an earnings per share ratio of -13.97.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.